Phibro Animal Health (PAHC) Given Daily Media Sentiment Rating of 0.30

Press coverage about Phibro Animal Health (NASDAQ:PAHC) has trended positive on Sunday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Phibro Animal Health earned a news sentiment score of 0.30 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.4523251148487 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Phibro Animal Health (NASDAQ:PAHC) opened at $36.20 on Friday. The stock has a market cap of $1,470.00, a PE ratio of 21.29, a P/E/G ratio of 4.20 and a beta of 1.27. The company has a debt-to-equity ratio of 1.91, a current ratio of 3.26 and a quick ratio of 1.85. Phibro Animal Health has a 12-month low of $26.10 and a 12-month high of $40.25.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Monday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.01. The firm had revenue of $193.40 million during the quarter, compared to analyst estimates of $189.89 million. Phibro Animal Health had a net margin of 8.87% and a return on equity of 42.75%. Phibro Animal Health’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.36 EPS. equities analysts forecast that Phibro Animal Health will post 1.57 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 27th. Investors of record on Wednesday, December 6th were given a $0.10 dividend. The ex-dividend date was Tuesday, December 5th. This represents a $0.40 dividend on an annualized basis and a yield of 1.10%. Phibro Animal Health’s dividend payout ratio is presently 23.53%.

A number of analysts recently weighed in on PAHC shares. BidaskClub cut shares of Phibro Animal Health from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 12th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Phibro Animal Health in a report on Friday, November 10th. ValuEngine lowered shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Finally, Zacks Investment Research lowered shares of Phibro Animal Health from a “hold” rating to a “sell” rating in a research report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $38.25.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at

About Phibro Animal Health

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Insider Buying and Selling by Quarter for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with's FREE daily email newsletter.

Leave a Reply